Preparation and characterisation of mucoadhesive nasal gel of venlafaxine hydrochloride for treatment of anxiety disorders
- PMID: 23716871
- PMCID: PMC3660869
- DOI: 10.4103/0250-474X.108418
Preparation and characterisation of mucoadhesive nasal gel of venlafaxine hydrochloride for treatment of anxiety disorders
Abstract
The aim of the present study is to prepare and evaluate mucoadhesive nasal gels of venlafaxine hydrochloride. Mucoadhesive nasal gels were prepared using polymers like carbopol 934 and sodium alginate and characterized in terms of viscosity, texture profile analysis, ex vivo drug permeation profiles and histopathological studies. The results show that values of viscosity, hardness and adhesiveness increase while those of cohesiveness decrease with corresponding increase in concentration of the polymers. Ex vivo drug permeation profiles showed that formulation containing 5% sodium alginate provided a better controlled release of the drug than the other formulations over a period of 12 h. Histopathological studies assured that gels containing different polymers did not produce any significant change in the nasal mucosae of goat even after 12 h permeation study. Mucoadhesive nasal gel of venlafaxine hydrochloride is a novel dosage form which delivers the drug directly into systemic circulation and provides controlled release of the drug.
Keywords: Mucoadhesive; nasal gel; novel dosage form; venlafaxine hydrochloride.
Figures



References
-
- Venlafaxine. [Last accessed 2011 Mar 20]. Available from: http://www.wikipedia.org .
-
- Howell SR, Hicks DR, Scantina JA, Sisenwine SF. Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. Xenobiotica. 1994;24:315–27. - PubMed
-
- Wyeth Laboratories. Philadelphia, PA: 2006. Effexor XR (venlafaxine hydrochloride) extended release capsules prescribing information.
-
- Sherman DM, Clark JC, Lamer JU, White SA. Extended release formulation containing venlafaxine. EP Patent No, EP0797991B1. 2004
-
- Sherman DM, Clark JC, Lamer JU, White SA. Extended release formulation containing venlafaxine. EP Patent No, EP1331003A1. 2003
LinkOut - more resources
Full Text Sources